So trying to think like a regulator I’d want a known biomarker like the vascular target found in the Roswell Park tech that NWBO has now but has not been fully validated by trial results yet OR perhaps the UK Specials data can be utilized as sufficient validation that the PROCESS of activation and maturation that NWBO utilizes is sufficient on its own to be determined as potentially tissue agnostic which opens up the new pathway for patient access moving forward while still being followed. This would be similar to the IFR pathway for access to treatment in the UK. Best wishes.
Market Data 
Markets 
AI
